Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Shionogi Takes Osaka Tax Bureau to Court
September 5, 2016
- Takeda to Develop Zika Vaccine with US Funding
September 5, 2016
- MSD Paid 15.2 Billion Yen to Doctors, Medical Institutions in 2015
September 5, 2016
- Oncolys to Evaluate Oncolytic Virus in Combination with Immune Checkpoint Inhibitors; Interim Results Expected in 2017
September 5, 2016
- Nippon Kayaku Seeks Add’l Dosage for Remicade Biosimilar in Psoriasis
September 2, 2016
- Takeda Kicks Off Global Observation Study for Multiple Myeloma
September 2, 2016
- Lilly, Osaka Univ. Join Forces on Obesity Research
September 2, 2016
- Chugai Transfers Marketing Authorization for Vesanoid to Fuji Pharma
September 2, 2016
- Sunovion to Acquire Canadian CNS Biotech: Sumitomo Dainippon
September 2, 2016
- Kipres/Singulair AG Hits Shelves in Japan: Kyorin Holdings
September 2, 2016
- Sandoz Taps Jason Hoffe as New Japan Head
September 2, 2016
- Otsuka, RIKEN Open Collaborative Research Center to Promote Regenerative Medicine
September 2, 2016
- Takecab Most Heavily Pitched Drug in July: Anterio
September 1, 2016
- Sovaldi Filed in Japan for All Hep C Genotypes Excluding Genotype 1: Gilead
September 1, 2016
- Pfizer Files Xalkori for ROS1-Positive Lung Cancer in Japan
September 1, 2016
- Harvoni Outstrips Plavix to Top FY2015 Japan Sales Ranking: Jiho Tally
September 1, 2016
- Kyowa Kirin Completes Construction of API Manufacturing Facility for Biopharmaceuticals
September 1, 2016
- Lonsurf Now Available in UK with Health Coverage: Taiho
August 31, 2016
- Data Support Lixiana’s Efficacy in AF Patients Undergoing Cardioversion
August 31, 2016
- Mitsubishi Tanabe’s ALS Drug Gets PDUFA Date of June 16, 2017
August 31, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…